Baltimore Sun

‘For the greater good’

Baltimore’s Black leaders volunteer for medical trials to fight against historical mistrust of research and improve community health

- By Tatyana Turner and Yvonne Wenger

Freeman Hrabowski III and his wife, Jacqueline, volunteere­d earlier this year to participat­e in a local clinical trial for the COVID-19 vaccine candidate developed by Moderna, which is now seeking federal authorizat­ion for its use.

The couple wanted to set an example for others in the Black community.

“There’s always a little fear, but we look at each other and say, ‘This is for the greater good,’ ” said Freeman Hrabowski, the president of University of Maryland, Baltimore County.

As many Americans eagerly wait for COVID-19 vaccines to be distribute­d, Black Baltimore leaders are working — with some success — to confront the glaring lack of people of color who participat­e in the important clinical trials needed to develop such medication­s.

African Americans represent just 5% of the people in most clinical trials, but make up12% of the U.S. population, according the U.S. Food and Drug Administra­tion. Not having enough people of color in medical trials can lead to problems with medication­s and treatments.

“There are issues of knowing whether a [COVID-19] vaccine will work on all subcategor­ies including race, gender and age,” said Dr. Matthew Laurens of Baltimore’s Center of Vaccine Developmen­t and

Global Health. “As humans we are 99% similar, but that 1% can make a big difference.”

Efforts to convince Black and brown people to participat­e in clinical trials are crucial to overcoming a sometimes racist past in medical research and to improving health outcomes for racial minorities, experts say. Consider that African Americans are twice as likely as white people to develop Alzheimer’s disease and Black residents of Maryland represent nearly 50% of COVID-19 deaths, but only make up 31% of the state’s population, according to Pew Research.

Starting in August, representa­tives of the Center of Vaccine Developmen­t at the University of Maryland School of Medicine handed out flyers around Baltimore and worked to connect with minority communitie­s. The goal was to find Black and brown people to participat­e in the Moderna clinical trial.

The trial was needed to determine whether the vaccine could prevent coronaviru­s infections. About 30,000 people were expected to participat­e at 89 sites, according to the National Institutes of Health. In Baltimore, 48 participan­ts took part in the trial at the University of Maryland, with more than 50% of the volunteers being people of color.

The trial participan­ts were given two intramuscu­lar injections, one month apart from each other. They either got two shots of the vaccine or two shots of a placebo. Volunteers didn’t know which one they were getting at the time of injection.

After it was over, Hrabowski said the couple felt sluggish for three days. They recorded their symptoms in a journal. They are also required to have blood work done every six months to track how their bodies are reacting.

Hrabowski said he doesn’t feel that he is putting his life on the line by participat­ing

in the trials.

“We have been educators and mentors for a long time,” he said. “We would not do something like this if we didn’t believe it was safe for other people.”

As the community effort to convince other reluctant potential volunteers continues, Thurka Sangaramoo­thy, a cultural anthropolo­gist with a background in pandemics, said health care profession­als need to ask themselves some serious questions about how to gain the trust of people of color.

“Do the people in the community know you? Are you an advocate? Are you competent in delivering a program aligned with the community?” Sangaramoo­rthy asked. “There are very few profession­als who can say ‘yes.’ They are just in a race to find a cure.”

Until those concerns are acknowledg­ed, Sangararmo­orthy said, mistrust between communitie­s of color and the medical field will remain an issue.

“A vaccine is called a magic bullet solution because it’s a quick fix, but people still feel like their concerns are being brushed off when they go to the doctor. That’s an issue a magic bullet can’t fix,” she said.

The Maryland vaccine developmen­t center is seeking participan­ts for another COVID-19 trial launching this month.

Laurens said the progress made on the current vaccines could not have happened without clinical trial volunteers.

“I think that we should thank all of the volunteers and consider them to be true American heroes,” he said.

The effort to encourage more Black participat­ion extends beyond clinical trials.

When Black people with certain health conditions die and their bodies end up in the Maryland medical examiner’s office, their families may receive a call asking a difficult question: Would the deceased’s loved ones agree to donate the person’s brain to science?

The call comes from a group of top-tier scientists, Black Baltimore leaders and

 ?? MATTHEW PAUL D’AGOSTINO/COURTESY PHOTO ?? Dr. Freeman Hrabowski, president of UMBC, receives a Moderna mRNA COVID-19 vaccine as a participan­t in a clinical trial.
MATTHEW PAUL D’AGOSTINO/COURTESY PHOTO Dr. Freeman Hrabowski, president of UMBC, receives a Moderna mRNA COVID-19 vaccine as a participan­t in a clinical trial.
 ?? AMY DAVIS/BALTIMORE SUN ?? Dr. Daniel R. Weinberger, left, and the Rev. Alvin Hathaway work together on the African Ancestry Neuroscien­ce Research Initiative.
AMY DAVIS/BALTIMORE SUN Dr. Daniel R. Weinberger, left, and the Rev. Alvin Hathaway work together on the African Ancestry Neuroscien­ce Research Initiative.

Newspapers in English

Newspapers from United States